Address
4 The Steadings
Home Farm
Luncarty, Perth & Kinross
PH1 3HE, United Kingdom
Contact
Michael Graz+447876598640
michael@biophys.co.uk
Website
Disperazol
Disperazol prevents formation of, and dismantles already established biofilm infections.
c-di-GMP is not produced by humans suggesting that c-di-GMP signalling is a promising, biofilm-specific drug target with reduced risk of side effects.
Technology:
Microorganisms:
Application:
Development stage:
- Antimicrobial compound/strategy
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Research
- Development
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Academia
- Company
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Sell
- Outsource
- Joint Venture
Funding organisation:
- OTHER / NA
- CARB-X
- FIND
- GARDP
- REPAIR
Infectious disease area:
- UTI
- RTI
- STI
- BSI
- GII
- SSTI
- CNSI
- IAI
- SSI
Geographic origin:
- Eurasia
- North America
- South America
- Africa
- Oceania
Expertise in, and infrastructure for, clinical development as well as access to finance. A strategic partner that will open pathways for engagement with PE Investors or VC’s to overcome the financial hurdles of executing Ph I trials.
Spin out from University of Copenhagen – Anti-biofilm Developer
Early stage development of c-di-GMP technology against E.coli.
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!